The latest price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) was reported by Citigroup on May 19, 2026. The analyst firm set a price target for $380.00 expecting ALNY to rise to within 12 months (a possible 28.27% upside). 66 analyst firms have reported ratings in the last year.

The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) was provided by Citigroup, and Alnylam Pharmaceuticals initiated their buy rating.

The last upgrade for Alnylam Pharmaceuticals Inc happened on February 17, 2026 when Freedom Broker raised their price target to $410. Freedom Broker previously had a hold for Alnylam Pharmaceuticals Inc.

The last downgrade for Alnylam Pharmaceuticals Inc happened on March 16, 2026 when Jefferies changed their price target from $522 to $330 for Alnylam Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on May 19, 2026 so you should expect the next rating to be made available sometime around May 19, 2027.

While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a initiated with a price target of $0.00 to $380.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $296.24, which is within the analyst’s predicted range.